Companies /Healthcare

Annovis Bio Inc

NYSE: ANVS Biotechnology
$0.93
▲ $0.08 (+9.31%) today
Markets closed · 12:32am ET

ANVS at a Glance

Valuation
Market cap
$39.8M
Profitability
EPS (TTM)
$-1.91
Price
52-week range
$1 – $6
Street target
$10.50

Headquartered in Malvern, PA Fiscal year ends December NYSE: ANVS annovisbio.com

About Annovis Bio

Annovis Bio, Inc. (NYSE: ANVS) is a Phase 3 clinical-stage, pre-revenue biotechnology company developing treatments for neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.

Its lead candidate, buntanetap (formerly posiphen), is an investigational once-daily oral small molecule. It inhibits the translation of multiple neurotoxic proteins through a specific RNA-targeting mechanism. These proteins include APP and amyloid beta, tau, alpha-synuclein, and TDP-43.

The company's main programs are:
- **DUET-AD:** a fully enrolled 862-patient pivotal Phase 3 trial in early Alzheimer's. It has two prespecified readouts: a 6-month symptomatic readout expected in March 2027 and an 18-month disease-modifying readout.
- **OLE-AD:** an Alzheimer's open-label extension study.
- **OLE-PD:** a 36-month Parkinson's open-label extension study with 326 patients enrolled.

Annovis is preparing a New Drug Application with support from AI regulatory partner Weave Bio. It funds operations through equity offerings, most recently a public offering of approximately $21.0 million in gross proceeds closed in November 2026. Updated

ANVS Coverage

Frequently Asked Questions

What does Annovis Bio do?

Annovis Bio, Inc. (NYSE: ANVS) is a Phase 3 clinical-stage, pre-revenue biotechnology company developing treatments for neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. Its lead candidate, buntanetap (formerly posiphen), is an investigational once-daily oral small molecule.

What is the ANVS stock price target?

The Wall Street consensus 12-month price target for ANVS is $10.50.